The financials
Alkermes plc by the numbers
Alkermes plc (ALKS) reported revenue of $393M in Q1 2026 (quarter ended Mar 31, 2026), up 28% from the same quarter a year earlier. That came with a gross margin of 84% and net loss of $66M. For the full year FY2025, revenue was $1.48B (−5.2% year on year) and net income $242M. Its largest product in Jun 2026 was Vivitrol at $124M, 23% of the disclosed total, just ahead of Aristada And Aristada Initio at 18%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $393M | $307M | +28% |
| Gross profit | $331M | $257M | +29% |
| Operating income | −$48M | $14M | to a loss |
| Net income | −$66M | $22M | to a loss |
| Diluted EPS | −$0.40 | $0.13 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Vivitrol | $124M | 23% |
| Aristada And Aristada Initio | $97M | 18% |
| LUMRYZ | $97M | 18% |
| LYBALVI | $94M | 17% |
| Manufactured Product And Royalty | $84M | 15% |
| Royalty | $27M | 5.0% |
| Manufacturing | $21M | 3.8% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $544.4M (+31%)
Manufacturing grew +183% year on yearRoyalty -9.4% year on year
Segment Latestquarter on quarteryear on year
- Vivitrol$124.5M$124.5MQoQ +11%year on year +2.3%+11%+2.3%
- Aristada And Aristada Initio$96.7M$96.7MQoQ +3.1%year on year -4.5%+3.1%-4.5%
- LUMRYZ$96.6M$96.6MQoQ +145%year on year -+145%-
- LYBALVI$94.0M$94.0MQoQ +1.7%year on year +12%+1.7%+12%
- Manufactured Product And Royalty$84.3M$84.3MQoQ +54%year on year +1.0%+54%+1.0%
- Royalty$27.5M$27.5MQoQ +53%year on year -9.4%+53%-9.4%
- Manufacturing$20.9M$20.9MQoQ +414%year on year +183%+414%+183%
Drug Manufacturers - Specialty & Generic
Ranks #20 of 29 by Smart Score